NCT05738694 - Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma | Biotech Hunter

Enrollment

246

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

July 16, 2025

Study Completion Date

March 16, 2026

Conditions

Renal Cell CarcinomaNeoadjuvant

Interventions

DRUG

Axitinib plus Toripalimab

Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.

PROCEDURE

nephrectomy

Trial Locations (8)

Unknown

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Peking University First Hospital, Beijing

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Anhui Provincial Hospital, Hefei

RECRUITING

Fudan University Cancer Hospital, Shanghai

RECRUITING

West China Hospital, Sichuan

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

RECRUITING

The First Affiliated Hospital of Zhengzhou Hospital, Zhengzhou